Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORA | P35398 | 5/20 | 0.49 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.48 |
| ▸ | MLYCD | O95822 | 7/20 | 0.47 |
| ▸ | RORC | P51449 | 6/20 | 0.44 |
| ▸ | RORB | Q92753 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2943579 | 0.90 | MLYCD (0.52) | RORANR1H3MLYCDRORCRORB | |
| SCHEMBL2940660 | 0.82 | RORA (0.55) | RORANR1H3MLYCDRORCRORB | |
| SCHEMBL2940775 | 0.78 | RORA (0.50) | RORANR1H3MLYCDRORCRORB | |
| SCHEMBL11412249 | 0.73 | RORA (0.63) | RORANR1H3RORCRORBSMN1; SMN2 | |
| SCHEMBL2944332 | 0.72 | NR1H3 (0.66) | RORANR1H3MLYCDRORCRORB | |
| SCHEMBL2944177 | 0.71 | NR1H3 (0.51) | NR1H3MLYCDSMN1; SMN2NR1H2GAA | |
| SCHEMBL12334564 | 0.70 | NR1H3 (0.59) | RORANR1H3MLYCDRORCRORB | |
| SCHEMBL11424113 | 0.70 | RORA (0.56) | RORANR1H3RORCRORBSMN1; SMN2 | |
| SCHEMBL3235447 | 0.68 | MLYCD (0.59) | RORAMLYCDRORCSMN1; SMN2NR1H4 | |
| SCHEMBL2943898 | 0.68 | RORA (0.53) | RORANR1H3RORCRORBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4503232-B2 | — | — | 2010-07-14 | — | — | JP | claimed |
| JP-2004521113-A | — | — | 2004-07-15 | — | — | JP | claimed |
| US-20040087627-A1 | Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-05-06 | — | — | US | claimed |
| EP-1353662-A2 | METHODS FOR THE TREATMENT OF DISEASES USING MALONYL-COA DECARBOX YLASE INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-10-22 | — | — | EP | claimed |
| WO-2002058690-A2 | METHODS FOR THE TREATMENT OF DISEASES USING MALONYL-COA DECARBOX YLASE INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-08-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087627-A1 | Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors | ME2, PC, ACACA | RORA 2055/4885NR1H3 1227/4885MLYCD 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.